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Abstract
Background: The multifunctional protein vitronectin is present within the deposits associated
with Alzheimer disease (AD), age-related macular degeneration (AMD), atherosclerosis, systemic
amyloidoses, and glomerulonephritis. The extent to which vitronectin contributes to amyloid
formation within these plaques, which contain misfolded, amyloidogenic proteins, and the role of
vitronectin in the pathophysiology of the aforementioned diseases is currently unknown. The
investigation of vitronectin aggregation is significant since the formation of oligomeric and fibrillar
structures are common features of amyloid proteins.
Results: We observed vitronectin immunoreactivity in senile plaques of AD brain, which exhibited
overlap with the amyloid fibril-specific OC antibody, suggesting that vitronectin is deposited at sites
of amyloid formation. Of particular interest is the growing body of evidence indicating that soluble
nonfibrillar oligomers may be responsible for the development and progression of amyloid diseases.
In this study we demonstrate that both plasma-purified and recombinant human vitronectin readily
form spherical oligomers and typical amyloid fibrils. Vitronectin oligomers are toxic to cultured
neuroblastoma and retinal pigment epithelium (RPE) cells, possibly via a membrane-dependent
mechanism, as they cause leakage of synthetic vesicles. Oligomer toxicity was attenuated in RPE
cells by the anti-oligomer A11 antibody. Vitronectin fibrils contain a C-terminal protease-resistant
fragment, which may approximate the core region of residues essential to amyloid formation.
Conclusion: These data reveal the propensity of vitronectin to behave as an amyloid protein and
put forth the possibilities that accumulation of misfolded vitronectin may contribute to aggregate
formation seen in age-related amyloid diseases.
Background
Vitronectin is a multi-functional glycoprotein involved in
a variety of physiological processes. It is present in blood
at a concentration of 0.2–0.45 mg/ml, constituting 0.1–
0.5% of plasma protein, and is a component of the extra-
cellular matrix [1,2]. While the liver is the primary site of
vitronectin synthesis, several extrahepatic sites have been
reported, including the retina [3-5], brain [6], and vascu-
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lar smooth muscle cells [7]. The multi-functional proper-
ties of vitronectin are mediated by its ability to interact
with many other macromolecules. Vitronectin inhibits
fibrinolysis through its N-terminal somatomedin B (SMB)
domain, which binds to and stabilizes type 1 plasmino-
gen activator inhibitor (PAI-1) [8,9]. Cell adhesion,
spreading, and migration is promoted by the interaction
of vitronectin's RGD sequence with several integrin recep-
tors, including the αvβ3 vitronectin receptor [10]. Vit-
ronectin associates with components of the extracellular
matrix via a collagen-binding domain and a polycationic
heparin-binding domain [11,12]. The C-terminal
heparin-binding domain also prevents complement-
mediated cell lysis by inhibiting assembly of the C5b-C9
membrane attack complex and blocking perforin pore for-
mation [13-15].
Whilst its role in maintaining homeostasis has been stud-
ied extensively, the role of vitronectin in disease is not
well understood, though it has been implicated in a
number of disease processes. For example, vitronectin
expression is upregulated in animal models of acute and
chronic inflammation [16] and in fibrotic tissues [17,18].
In addition, serum levels of vitronectin are elevated in
patients with atherosclerosis [19], type 2 diabetes [20],
and Alzheimer disease (AD) [20]. Vitronectin has been
identified in deposits associated with AD, atherosclerosis,
systemic amyloidoses, and glomerulonephritis [21-33]. In
addition, we and others [4,5,26,27,34-36] have observed
vitronectin reactivity in all drusen samples analyzed,
which are extracellular ocular deposits associated with
aged eyes and eyes with age-related macular degeneration.
Accumulation of vitronectin in extracellular deposits may
be related to its proclivity to undergo structural rearrange-
ments and its tendencies to self-associate and form mul-
timers and high molecular aggregates in vitro, even under
near physiological conditions [37-39]. The structural basis
for the tendency of vitronectin to aggregate is incom-
pletely understood. It has been observed that these insol-
uble vitronectin-containing disease deposits exhibit
thioflavin staining [40-42], indicating an underlying proc-
ess of protein misfolding and amyloid formation. In this
study we address whether formation of amyloid structures
may be a product of vitronectin misfolding. The investiga-
tion of vitronectin aggregation is significant since the for-
mation of spherical and protofibrillar oligomers, as well
as fibrils, are common properties of amyloid proteins,
although they share neither sequence nor native structural
homology. A growing body of evidence indicates that sol-
uble prefibrillar oligomers may be the primary pathogenic
species in amyloidopathies [43-47]. Thus, if vitronectin
does indeed form amyloid oligomers or fibrils, its mis-
folding may contribute to the pathophysiology of the
aforementioned diseases.
The development of the conformation-specific A11 anti-
body which recognizes soluble nonfibrillar oligomers
made from a number of amyloidogenic peptides and pro-
teins, but not monomers or fibrils, has aided the analysis
of these toxic aggregates [48]. This antibody facilitates the
characterization of soluble oligomers as markers of amy-
loid diseases and enables the identification of novel amy-
loid diseases wherein there is oligomer accumulation
without abundant fibril deposition. One such disease is
desmin-related cardiomyopathy [49,50]. We recently
reported that human ocular drusen contain nonfibrillar
oligomers, which suggests that age-related macular degen-
eration may be another example of this type of amyloido-
sis [35], and a number of studies identify vitronectin as
one of the most abundant drusen proteins [4,26,34,51].
Vitronectin is an appealing candidate for misfolding due
to its widespread distribution in the body and its associa-
tion with insoluble, disease-associated plaques. In this
study, we demonstrate that vitronectin behaves as an amy-
loid protein in vitro and soluble nonfibrillar vitronectin
oligomers are toxic to cultured cells. Amyloidogenic pro-
pensity and toxicity suggest that vitronectin misfolding
and aggregation may contribute to the pathophysiology
of age-related diseases.
Results
Vitronectin deposits in senile plaques of Alzheimer brain
In order to assess the presence of vitronectin in extracellu-
lar deposits, we examined Alzheimer disease brain. In the
senile plaques of AD brain, Aβ reactivity (Figure 1, upper
panel, red) showed extensive overlap with the OC anti-
body (Figure 1 upper panel, green) which specifically rec-
ognizes amyloid fibrils and fibrillar oligomers. Lipofuscin
autofluorescence is seen in the red channel together with
Aβ but is not visible in the green channel. It can thus be
distinguished by the red fluorescence. Similarly, robust
vitronectin staining (Figure 1, lower panel, green) exhib-
ited extensive overlap with OC reactivity in the plaques
(Figure 1, lower panel, red). Overall, in the four cases of
AD brain we examined there was a high correspondence
of vitronectin reactivity in amyloid plaques, suggesting
that vitronectin accumulates specifically in extracellular
deposits that contain amyloid species.
Vitronectin forms soluble nonfibrillar oligomers and 
amyloid fibrils
To investigate whether vitronectin has an inherent pro-
pensity to behave as an amyloid protein, we aged plasma-
purified and recombinant human vitronectin in phos-
phate-buffered saline (PBS). Plasma-purified and recom-
binant vitronectin in PBS form spherical and fibrillar
structures by TEM (Figure 2, left). Because vitronectin in
PBS produces a heterogeneous mixture of aggregates, we
used 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP), a com-
monly used solvent which enhances the rate of aggrega-Molecular Neurodegeneration 2008, 3:16 http://www.molecularneurodegeneration.com/content/3/1/16
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tion [52,53], to enrich the fibril and oligomer
populations. Treatment with 50% HFIP promotes the for-
mation of vitronectin fibrils, which resemble the mor-
phology of typical amyloid fibrils (Figure 2, middle). The
fibrils are approximately 3–8 nm in diameter, of varied
length, and often twisted. Plasma-purified and recom-
binant vitronectin incubated in 20% HFIP and 1 mM HCl
adopt spherical and protofibrillar structures, which range
in size from 6–35 nm in diameter (Figure 2, right). Both
vitronectin oligomers and fibrils enhance thioflavin T flu-
orescence (data not shown).
A11-positive vitronectin oligomers are toxic to SH-SY5Y 
and RPE cells and induce membrane leakage
To further characterize recombinant vitronectin oligom-
ers, we performed a dot blot assay using the conforma-
tion-specific A11 antibody, which recognizes toxic
oligomers formed by a variety of amyloidogenic proteins.
Recombinant vitronectin freshly dissolved in phosphate
buffer (Figure 3A) and vitronectin treated with 50% HFIP
to induce fibrils (Figure 3C) are not recognized by the A11
antibody. However, recombinant vitronectin incubated in
20% HFIP and 1 mM HCl exhibits A11 immunoreactivity
(Figure 3B), suggesting that the population of soluble
nonfibrillar oligomers is enriched under these conditions.
The quantity of vitronectin on the membrane was
assessed using a primary anti-vitronectin antibody (Figure
3F–I). Aβ oligomers (Figure 3D) served as a positive con-
trol for the A11 antibody, but were not recognized by the
vitronectin antibody, as expected (Figure 3H).
Recent evidence suggests soluble nonfibrillar oligomers
may comprise a toxic species. Because A11 immunoreac-
tivity has been reported to correlate with cytotoxicity and
recombinant vitronectin oligomers are A11-positive, we
examined their effects on cultured SH-SY5Y and retinal
pigment epithelium (RPE) cells. SH-SY5Y neuroblastoma
cells and RPE cells were chosen due to the emerging role
of soluble oligomers as pathogenic entities in neurode-
generative diseases such as Alzheimer disease and age-
related macular degeneration. HFIP was removed by evap-
oration and indicated concentrations of recombinant vit-
ronectin oligomers diluted in serum-free DMEM were
added to cells for 4 hours at 37°C. Cell viability was
assessed spectrophotometrically using an MTT-based
assay. Vitronectin oligomers were toxic to both SH-SY5Y
and RPE cells in a dose-dependent manner, as observed by
impaired MTT reduction (Figure 4, white and grey bars).
Plasma-purified and recombinant vitronectin aged in PBS
exhibited mild RPE toxicity (Figure 4, hatched bars). Pre-
Vitronectin deposits in senile plaques of Alzheimer disease brain Figure 1
Vitronectin deposits in senile plaques of Alzheimer disease brain. Upper panel: senile plaques of AD brain visualized 
with the OC antibody (green) and the 6E10 antibody against Aβ (red). Lower panel: vitronectin (green) reactivity shows exten-
sive overlap with OC reactivity (red), suggesting that vitronectin is deposited at sites of amyloid formation. Co-localization 
appears as yellow-orange color, while lipofuscin autofluorescence is seen predominantly in the red channel. Nuclei were visual-
ized with DAPI (blue). Scale bar = 10 μm.Molecular Neurodegeneration 2008, 3:16 http://www.molecularneurodegeneration.com/content/3/1/16
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incubation of 5 μM recombinant vitronectin oligomers
with an equimolar amount of A11 antibody prior to treat-
ment significantly attenuated the impairment in MTT
reduction, indicating oligomer-specific toxicity (Figure 4,
black bar) and demonstrating the ability of the A11 anti-
body to block the majority of toxic oligomeric species.
It has been suggested that the plasma membrane is a com-
mon target of toxic nonfibrillar oligomers. To investigate
the hypothesis that vitronectin oligomers disrupt mem-
brane integrity, we employed a fluorescence-based leak-
age assay using large unilamellar vesicles (LUVs) of 100
nm diameter loaded with the fluorophore-quencher pair
ANTS-DPX. Indicated concentrations of freshly-dissolved
recombinant vitronectin or recombinant vitronectin oli-
gomers were diluted in Buffer 1 (see Materials and Meth-
ods) containing 500 μM lipids. ANTS fluorescence was
monitored over time at 520 nm (λex = 353 nm) and per-
cent leakage was estimated by dividing the sample and
maximum fluorescence intensity values after correcting
for the intrinsic fluorescence of the vesicles. Freshly-dis-
solved recombinant vitronectin had no appreciable effect
on membrane permeability (Figure 5, white bars). Vit-
ronectin oligomers induced dose-dependent leakage of
ANTS from LUVs (Figure 5, grey bars), indicating that
membrane disruption is caused by the oligomeric confor-
mation.
Trypsin digestion of vitronectin fibrils reveals a protease-
resistant core
To facilitate the isolation and identification of the amy-
loidogenic core of vitronectin fibrils, we employed pro-
tease digestion followed by peptide sequencing,
immunoblotting, and mass spectrometry analysis. Undi-
gested vitronectin fibrils are shown in Figure 6A (lane 1).
It is evident that a large amount of aggregated protein was
Human vitronectin forms amyloid fibrils and oligomers Figure 2
Human vitronectin forms amyloid fibrils and oligomers. Left, Plasma-purified (hVn) and recombinant human vitronectin 
(rVn) aged in phosphate-buffered saline form a heterogeneous mixture of spherical and fibrillar structures as seen under TEM. 
Middle, Vitronectin treated with 50% HFIP promotes the formation of typical amyloid fibrils that are approximately 3–8 nm in 
diameter. Right, Incubation in 20% HFIP and 1 mM HCl enriches the population of spherical and protofibrillar oligomers, which 
range from 6–35 nm in diameter. Scale bar = 100 nm.Molecular Neurodegeneration 2008, 3:16 http://www.molecularneurodegeneration.com/content/3/1/16
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not resolved by SDS-PAGE and was retained in the wells
or did not pick up the Coomassie stain (Figure 6A, aster-
isk). Trypsin digestion of vitronectin fibrils produced a
major protease-resistant fragment of ~5 kDa (Figure 6A,
lane 2). This band was not present when soluble recom-
binant vitronectin was digested (data not shown). Partial
protein sequencing of the first twenty-one amino acids by
N-terminal Edman degradation identified the peptide
AMWLSLFSSEESNLGANNYDD in the excised band,
which comprises C-terminal residues 380–400. The origin
of the peptide was confirmed by western blot with a C-ter-
minal-specific vitronectin antibody (data not shown).
MALDI-TOF mass spectrometry analysis of the excised
fragment identified several vitronectin peptides (Figure
6B) and suggests that residues 380–427 may be important
for amyloid formation. The peptides correlate well with C-
terminal stretches of increased cross-beta aggregation pro-
pensity as predicted by the TANGO algorithm (Figure 6B).
Discussion
In this study, we demonstrate that in the AD brain, vit-
ronectin and the fibril-specific OC antibody showed
extensive overlap within senile plaques, suggesting that
vitronectin may participate in amyloid formation at those
sites. Importantly, we provide evidence that vitronectin is
capable of amyloid formation. Consistent with previous
reports [37-39], we observed that vitronectin readily
forms aggregates, even in physiologic buffer. In this study
we demonstrate that such aggregates display amyloid
structures. These results extend previous in vitro studies of
vitronectin aggregation and provide a possible structural
basis for such oligomerization. HFIP treatment, although
not required, enriched the individual populations of sol-
uble, spherical oligomers and amyloid fibrils. Our results
establish the amyloidogenicity of vitronectin and are in
agreement with previously published reports regarding
the toxicity of soluble oligomers [54]. The finding that
HFIP treatment enhances oligomer and fibril formation
supports the hypothesis that partial unfolding or denatur-
Vitronectin forms soluble nonfibrillar amyloid oligomers Figure 3
Vitronectin forms soluble nonfibrillar amyloid oligomers. Samples were spotted on a nitrocellulose membrane and 
probed with either A11 (A-D) or vitronectin (E-H) primary antibodies. Recombinant vitronectin (rVn) incubated in 20% HFIP 
and 1 mM HCl exhibits reactivity to the oligomer-specific A11 antibody (B), whereas vitronectin freshly dissolved in phosphate 
buffer (A) or treated with 50% HFIP (C) do not, suggesting that treatment with 20% HFIP enriches the population of soluble 
oligomers. Reactivity of samples with the vitronectin antibody confirms the presence of protein (E-G). Aβ oligomers served as 
a positive control for the A11 antibody (D), but are not detected by the vitronectin antibody (H).Molecular Neurodegeneration 2008, 3:16 http://www.molecularneurodegeneration.com/content/3/1/16
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ation of the native protein state promotes misfolding and
subsequent formation of amyloid structures [55]. Vit-
ronectin is known to accumulate in extracellular deposits
in the eye and brain that are associated with macular
degeneration and Alzheimer disease, respectively
[4,21,24,27,33]. Interestingly, vitronectin oligomers rec-
ognized by the conformation-specific A11 antibody are
cytotoxic to cultured RPE and SH-SY5Y cells in a dose-
dependent manner. Soluble oligomers formed in vitro
from a variety of proteins appear morphologically similar
and exhibit toxicity to cultured cells [48,54,56-63], sug-
gesting a common pathogenic mechanism. Pre-incuba-
tion of vitronectin oligomers with the A11 antibody prior
to treatment significantly rescued RPE cell viability, dem-
onstrating that the majority of toxic nonfibrillar oligom-
ers are neutralized by the A11 antibody. Vitronectin
oligomers permeabilize synthetic vesicles in a cell-free
Soluble nonfibrillar vitronectin oligomers compromise cell viability Figure 4
Soluble nonfibrillar vitronectin oligomers compromise cell viability. Recombinant vitronectin (rVn) oligomers are 
toxic to SH-SH5Y (white bars) and RPE cells (grey bars) in a dose-dependent manner, as evidenced by impaired MTT reduc-
tion. Plasma-purified (hVn) and recombinant vitronectin aged in PBS exhibit mild toxicity (hatched bars). RPE toxicity was sig-
nificantly attenuated when 5 μM recombinant vitronectin oligomers were pre-incubated with an equimolar amount of A11 
antibody prior to treatment (black bar), although complete rescue was not observed. Cell viability was assessed spectrophoto-
metrically using an MTT-based assay. Error bars represent standard error of the mean. (n = 3; **p < 0.01).Molecular Neurodegeneration 2008, 3:16 http://www.molecularneurodegeneration.com/content/3/1/16
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assay, which is consistent with studies showing that solu-
ble amyloid oligomers disrupt membranes [52,62,64-67].
Vitronectin fibrils resemble the morphology of typical
amyloid fibrils and contain a protease-resistant domain
which likely contains the core residues sufficient for amy-
loid formation. The trypsin-resistant band was seen by
SDS-PAGE and Coomassie stain when vitronectin fibrils
were digested, but not when soluble recombinant vit-
ronectin was digested. Sequencing and immunoblotting
of the fragment revealed a C-terminal epitope and mass
spectrometry analysis identified several peptides within
residues 380–427, indicating that this region may be
important for amyloid formation. Interestingly, the iden-
tified fragments overlap with two C-terminal regions that
have increased cross-beta aggregation propensity, as cal-
culated by the TANGO algorithm [68]. This region has
been predicted to have a beta-propeller like domain in
solution [69]. The combined data from mass spectrometry
and TANGO analysis suggest the existence of an ordered
amyloid core which limits protease accessibility to the
stretch of amino acids between the two predicted aggrega-
tion-prone regions. The putative amyloid core resides
within a naturally-occurring 10 kDa fragment (residues
380–459). Primary sequence analysis of the 10 kDa vit-
ronectin fragment reveals a stretch of highly hydrophobic
amino acids, which is consistent with the hypothesis that
hydrophobicity is a key factor in aggregation propensity
[55,68,70-72]. Further studies are warranted to precisely
delineate the boundaries of the vitronectin amyloidogenic
core and to characterize the in vitro and in vivo significance
of the 10 kDa vitronectin fragment.
Vitronectin exists in two distinct conformations in vivo.
The majority of vitronectin in plasma and serum circulates
as a non-heparin-binding monomer. Approximately 2–
8% of vitronectin in the blood is in the alternate heparin-
binding, partially unfolded conformation which can self-
associate [73]. This multimeric form is thought to be the
predominant conformation of vitronectin in the extracel-
lular matrix [74]. Chaotropic denaturation, which was
used in the purification of recombinant vitronectin,
exposes the heparin-binding site [37]. Since vitronectin
readily aggregates in its heparin-binding state, this specific
conformation may aid in amyloid formation, a hypothe-
sis further supported by the observation that hydrophobic
interactions appear to drive functional oligomerization
[75]. Interestingly, the protease-resistant region is located
adjacent to the heparin-binding domain.
Conclusion
Although a relatively small percentage of vitronectin is in
an alternate conformation, conditions of high local con-
centration via increased synthesis or recruitment, which
may occur at extravascular sites or in the setting of chronic
inflammation, may promote vitronectin misfolding and
amyloid formation. Our results put forth the possibility
that vitronectin misfolding and amyloid formation may
contribute to age-related diseases such as atherosclerosis,
AMD, and AD.
Methods
Antibodies and reagents
Plasma-purified vitronectin was purchased from Bio-
source (Camarillo, CA). The 6E10 antibody against beta-
amyloid (Aβ) 1–16 was purchased from Covance
Research Products, Inc. (Dedham, MA). The anti-oligomer
A11 antibody and OC antisera were generated as previ-
ously described [48,76]. Production of a polyclonal anti-
vitronectin antibody raised against full-length recom-
binant vitronectin was performed by Biomer Technology
(Hayward, CA). The IgG fraction was enriched from rabbit
serum using Affi-Gel Protein A support (Bio-Rad; Her-
cules, CA). Secondary antibodies were purchased from
Vector Laboratories (Burlingame, CA). All other reagents
Vitronectin oligomers induce membrane leakage Figure 5
Vitronectin oligomers induce membrane leakage. 
Large unilamellar vesicles (100 nm in diameter) loaded with 
the fluorophore-quencher pair ANTS-DPX were incubated 
with indicated concentrations of protein. Recombinant vit-
ronectin oligomers incubated with 500 μM LUVs resulted in 
appreciable leakage of vesicles in a dose-dependent fashion 
(grey bars) as compared to recombinant vitronectin freshly 
dissolved in phosphate buffer (white bars). Membrane leak-
age was assessed by monitoring ANTS fluorescence (λex = 
353 nm, λem = 520 nm). Intensities were normalized to the 
intrinsic fluorescence of the vesicles and percent leakage was 
estimated by dividing the sample and maximum fluorescence 
intensity values. Data shown are the combined average of 
three independent experiments. Error bars represent the 
standard error of the mean.Molecular Neurodegeneration 2008, 3:16 http://www.molecularneurodegeneration.com/content/3/1/16
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were purchased from Sigma-Aldrich (St. Louis, MO),
unless otherwise specified.
Immunocytochemistry
Frozen human cortex was obtained from the USC Alzhe-
imer Disease Research Center. Intact human eyes were
obtained from the Oregon Lions Sight and Hearing Foun-
dation. Tissue was prepared as described previously [35].
Briefly, sections were blocked overnight in phosphate-
buffered saline containing 2% BSA and 2% goat serum,
followed by incubation with either the anti-vitronectin
antibody or OC antisera. Sections were washed and incu-
bated with either FITC- or Texas Red-conjugated goat anti-
rabbit antibody. DAPI was used to visualize nuclei.
Images were acquired on an UltraVIEW VoX spinning disk
confocal microscope (PerkinElmer, Waltham, Massachu-
setts).
Cloning, expression, and purification of full-length human 
vitronectin
A plasmid containing human vitronectin cDNA was pur-
chased from American Tissue Culture Company (ATCC;
Rockville, MD) and a 1,385 bp fragment of mature, full-
length human vitronectin cDNA containing engineered
N-terminal NcoI and C-terminal HindIII restriction sites
was synthesized by polymerase chain reaction. The frag-
ment was digested with NcoI and HindIII restriction
enzymes (New England Biolabs; Ipswich, MA) and sub-
cloned into a pSE420 vector with complementary sticky
ends. Correct orientation of the insert was verified by
DNA sequencing and Escherichia coli DH5α cells were
Vitronectin fibrils contain a protease-resistant core Figure 6
Vitronectin fibrils contain a protease-resistant core. A) In-solution trypsin digestion of vitronectin fibrils reveals a pro-
tease-resistant band of ~5 kDa (lane 2). Partial sequencing by N-terminal Edman degradation identified the peptide AMWLSLF-
SSEESNLGANNYDD, which corresponds to residues 380–400. These amino acids reside in the C-terminus of the protein and 
likely comprise a portion the amyloidogenic core. This result was confirmed by immunoblotting with a C-terminal-specific anti-
body (data not shown). Arrowheads indicate molecular weight (kDa). Lane 1 contains undigested vitronectin fibrils, much of 
which is unresolved (asterisk). B) Upper panel: Several peptides were identified by MALDI-TOF analysis of the protease-resist-
ant band. The mass/charge (m/z) values, amino acid sequence and residue numbers are displayed in the table. Each m/z does 
not correspond to any other vitronectin peptides and oxidation had to be invoked for peptide A380-R427. Lower panel: Pri-
mary sequence analysis of vitronectin using the TANGO algorithm [68] reveals several C-terminal stretches prone to cross-
beta aggregation, two of which correlate well with the peptides A380-R402 (gray) and A380-R427 (hatched) identified by mass 
spectrometry. Y-axis denotes relative cross-beta aggregation propensity.Molecular Neurodegeneration 2008, 3:16 http://www.molecularneurodegeneration.com/content/3/1/16
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transformed with the 4.27 kb construct. Cells were grown
with shaking at 37°C to an optical density of 0.6–0.8 and
protein expression was induced by the addition of 1 mM
isopropyl-1-thio-β-D-galactopyranoside (IPTG) for 4
hours at 37°C. Cells were harvested by centrifugation at
5,000 × g for 15 minutes and the pellet was stored at -
80°C. Vitronectin protein was purified using a previously
described protocol [77] with modifications. The pellet
was resuspended in lysis buffer [5 mM EDTA, 10 mM
dithiothreitol (DTT), 1 mg/mL lysozyme, protease inhib-
itors, all in 10 mM sodium phosphate buffer, pH 7.4],
incubated on ice for 1 hour, then nutated at 4°C for 10
minutes with the addition of 24 U/ml DNase I, 60 mM
MgCl2, and 1% Triton X-100. The suspension was soni-
cated 3 × 1 minute on ice, with one minute between son-
ications, and centrifuged at 20,000 × g for 30 minutes. The
pellet was resuspended in 2 M urea buffer (2 M urea, 5
mM EDTA, 10 mM DTT, protease inhibitors, all in 10 mM
sodium phosphate buffer, pH 7.4), sonicated on ice, cen-
trifuged, and supernatant decanted. The resulting pellet of
inclusion bodies was solubilized in cold 8 M urea buffer
(8 M urea, 5 mM EDTA, 10 mM DTT, protease inhibitors,
all in 10 mM sodium phosphate buffer, pH 7.4), soni-
cated on ice, and centrifuged. The supernatant was
applied to a HiTrap heparin affinity column (Amersham
Biosciences; Piscataway, NJ) equilibrated with 8 M urea
buffer and proteins were eluted using a linear NaCl gradi-
ent. Vitronectin-containing fractions were identified by
SDS-PAGE, pooled, and dialyzed against 1% acetic acid,
10 mM phosphate buffer (pH 7.4), or PBS. Protein purity
was >95% by Coomassie Blue staining. Protein concentra-
tion was calculated from absorbance at 280 nm (εM =
82,330 M-1 cm-1).
Fibril and oligomer preparation
Lyophilized vitronectin protein in a siliconized microcen-
trifuge tube was dissolved in cold 1,1,1,3,3,3-hexafluoro-
2-propanol (HFIP) for 10 minutes at room temperature.
For fibrils, this solution was diluted to 50% HFIP in water
and stirred at room temperature for 7–14 days at a protein
concentration of 10–25 μM. Fibril formation was moni-
tored by transmission electron microscopy (TEM). To pre-
pare soluble oligomers, vitronectin in HFIP was diluted to
20% HFIP and 1 mM HCl and stirred at room temperature
with a vented lid for 3–7 days. The final protein concen-
tration was approximately 20 μM after the gradual evapo-
ration of HFIP. Oligomer formation was monitored by
TEM and by dot blot using the anti-oligomer antibody.
Alternatively, lyophilized vitronectin was resuspended in
PBS and aged for 2–4 weeks at room temperature with or
without stirring to form oligomers and fibrils without
HFIP.
Electron microscopy
HFIP was evaporated under a gentle stream of nitrogen.
Ten microliters of sample was applied to a 200-mesh
formvar-coated nickel grid (Electron Microscopy Sciences;
Hatfield, PA) for 5 minutes, stained in 3% uranyl acetate
for 5 minutes, rinsed, and air-dried. The grids were exam-
ined using a Jeol JEM1200EX microscope at 80 kV.
Dot blot
Two microliters of each sample were spotted onto nitro-
cellulose membrane and allowed to air-dry. Tris-buffered
saline (20 mM Tris, 0.8% NaCl, pH 7.4) containing
0.001% Tween-20 (TBST) was used for washing and dilu-
tion. The membrane was blocked for 1 hour with 10%
nonfat dried milk in TBST, washed 3 × 10 minutes, incu-
bated for one hour in primary anti-oligomer antibody
(1:5,000 in 3% BSA/TBST), washed 3 × 10 minutes, incu-
bated for 30 minutes in HRP-conjugated secondary anti-
rabbit antibody (1:10,000 in 3% BSA/TBST), and washed
3 × 10 minutes. The membrane was developed using
enhanced chemiluminescence reagents (Amersham Bio-
sciences; Piscataway, NJ) and exposed to Hyperfilm
(Amersham Biosciences; Piscataway, NJ). The same proce-
dure was performed for dot blot with anti-vitronectin
antibody (1:10,000; Biomer Technology, Hayward, CA)
using 0.1% Tween-20 in TBST. A control membrane with
primary antibody omitted was simultaneously processed.
Cell culture
SH-SY5Y cells were obtained from ATCC (Rockville, MD).
Retinal pigment epithelium (RPE) cells were isolated from
human fetal eyes obtained from Advanced Bioscience
Resources, Inc. (Alameda, CA) as described previously
[78]. Cells were maintained in complete medium [Dul-
becco's modified Eagle's medium (DMEM, VWR; West
Chester, PA) supplemented with 2 mM L-glutamine, 100
U/ml penicillin, 100 μg/ml streptomycin, and 10% fetal
bovine serum (Invitrogen; Carlsbad, CA)] at 37°C in a
humidified incubator. Fourth-passage cells were seeded in
a 96-well plate at 2 × 104 cells per well and grown in com-
plete medium for 3–4 days to approximately 90% conflu-
ence. Cells were maintained in serum-free medium for
one day prior to the experiment. On the day of the assay,
media was removed, replaced with the indicated samples
diluted in DMEM, and incubated at 37°C for 4 hours.
MTT (3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyl tetrazo-
lium bromide) dissolved in DMEM was added and cells
were placed at 37°C for an additional 4 hours. Tetrazo-
lium crystals were dissolved by the addition of MTT solu-
bilization solution (10% Triton X-100, 0.1 N HCl in
anhydrous isopropanol), and absorbance was measured
at 570 nm. Experiments were carried out in triplicates.Molecular Neurodegeneration 2008, 3:16 http://www.molecularneurodegeneration.com/content/3/1/16
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Membrane leakage
Large unilamellar vesicles (LUVs,100 nm diameter) con-
taining 90% phosphatidylcholine and 10% phosphatidyl-
serine (Avanti Polar Lipids; Alabaster, AL) were extruded
in the presence of the fluorophore-quencher pair 8-ami-
nonaphthalene-1,3,6-trisulfonic acid (ANTS) and p-
xylene-bis-pyridinium bromide (DPX). To assess mem-
brane leakage, a 250 μl solution containing 500 μM LUVs
and the sample of interest in Buffer 1 (10 mM HEPES, 50
mM KCl, 1 mM EDTA, 3 mM sodium azide) was placed in
a 2 mm path-length quartz cuvette. ANTS fluorescence
was monitored as a function of time at 520 nm with exci-
tation at 353 nm using a Jasco FP-6500 spectrofluorime-
ter. Maximum fluorescence intensity was determined by
adding 5 μl of 10% Triton X-100. Intensities were normal-
ized to the intrinsic fluorescence of the vesicles and per-
cent leakage was estimated by dividing the sample and
maximum fluorescence intensity values. The data repre-
sent the results of three independent experiments.
Protease digestion
Fibrils were collected by centrifugation and the pellets
were digested in a solution containing 1:25 trypsin (pro-
tease-to-protein mass ratio) and 10 mM DTT, all in 50
mM ammonium bicarbonate, pH 8, at 37°C. Overnight
digests were heat inactivated at 60°C, analyzed by SDS-
PAGE, and visualized with Coomassie Blue staining. The
major protease-resistant fragment was either transferred
onto a PVDF membrane and submitted to the USC/Norris
Microchemical Core Facility for peptide sequencing by N-
terminal Edman degradation, or excised and passively
eluted in 50 mM Tris, 50 mM NaCl (pH 8) and submitted
to the USC Proteomics Core Facility for matrix-assisted
laser desorption/ionization time-of-flight (MALDI-TOF)
mass spectrometry analysis.
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